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Abstract
The neurochemical profile of the striatum of R6/2 Huntington’s
disease mice was examined at different stages of pathogen-
esis using in vivo 1H NMR spectroscopy at 9.4 T. Between 8
and 12 weeks, R6/2 mice exhibited distinct changes in a set of
17 quantifiable metabolites compared with littermate controls.
Concentrations of creatine, glycerophosphorylcholine, gluta-
mine and glutathione increased and N-acetylaspartate
decreased at 8 weeks. By 12 weeks, concentrations of
phosphocreatine, taurine, ascorbate, glutamate, and myo-
inositol increased and phophorylethanolamine decreased.
These metabolic changes probably reflected multiple pro-
cesses, including compensatory processes to maintain
homeostasis, active at different stages in the development of
HD. The observed changes in concentrations suggested
impairment of neurotransmission, neuronal integrity and
energy demand, and increased membrane breakdown, glio-
sis, and osmotic and oxidative stress. Comparisons between
metabolite concentrations from individual animals clearly dis-
tinguished HD transgenics from non-diseased littermates and
identified possible markers of disease progression. Metabolic
changes in R6/2 striata were distinctly different from those
observed previously in the quinolinic acid and 3NP models of
HD. Longitudinal monitoring of changes in these metabolites
may provide quantifiable measures of disease progression
and treatment effects in both mouse models of HD and
patients.
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Huntington’s disease (HD) is characterized initially by
selective degeneration of medium spiny GABAergic projec-
tion neurons in the neostriatum (Vonsattel et al. 1985), and
involves progressive motor, cognitive, and psychiatric dys-
function (Huntington 1872; Nance 1998). Huntington’s
disease is caused by an expansion of the CAG repeat region
beyond 37 trinucleotides with age of onset inversely
proportional to repeat length (Huntington’s Disease Colla-
borative Research Group. 1993; Duyao et al. 1993). The
precise mechanism of HD pathophysiology is unknown,
although substantial evidence exists for multiple degenerat-
ive pathways, including mitochondrial impairment, oxidative
stress, caspase activation and apoptosis, impaired gene
transcription, and altered protein activity and interactions
(Landles and Bates 2004; Li and Li 2004; Beal 2005).
Critical insights into the pathophysiology of HD can be
derived from direct longitudinal studies of the CNS in pre-
symptomatic and affected HD patients (Rosenblatt et al.
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2003; Aylward et al. 2004). However, because of the
inherent difﬁculties in accessing human CNS tissue, bio-
chemical studies of HD have been performed on post-
mortem specimens, non-CNS tissues, such as lymphoblasts
or muscle, or extracellular sources, such as serum or
cerebrospinal ﬂuid (Dunlop et al. 1992; Nicoli et al. 1993;
Sawa et al. 1999; Lodi et al. 2000; Garseth et al. 2000).
In vivo 1H nuclear magnetic resonance (NMR) spectro-
scopy is a unique method for non-invasive quantiﬁcation of
tissue metabolites. It has been used to examine neurochem-
ical changes in multiple neurological disorders, including
epilepsy, brain tumors, multiple sclerosis, stroke, and
Parkinson’s and Alzheimer’s disease (Bonavita et al. 1999).
Previous 1H NMR spectroscopic studies in HD patients have
reported changes in signal intensity ratios of four brain
metabolites: N-acetylaspartate (NAA), total creatine (tCr),
choline-containing compounds (Cho), and lactate (Jenkins
et al. 1993; Koroshetz et al. 1997; Harms et al. 1997;
Jenkins et al. 1998). In majority of studies, the tCr signal was
used as an internal reference. However, reported changes in
tCr levels (Sanchez-Pernaute et al. 1999) make interpretation
of such ratios difﬁcult.
Development of a number of mouse models of HD have
provided rich resources for studying disease progression
(Levine et al. 2004). Long echo-time in vivo 1H NMR
spectroscopy has been used to monitor the decrease of NAA/
tCr signal ratio during disease progression in several different
genetic mouse models of HD (Jenkins et al. 2000; van
Dellen et al. 2000; Jenkins et al. 2005). In addition, changes
in signal intensity of Cho, taurine (Tau), and the sum of
glutamine and glutamate (Glx) relative to tCr were reported
for 12-week-old R6/2 and N171-82Q HD mice (Jenkins
et al. 2005). In vitro 1H NMR spectroscopy of brain tissue
extracts (Jenkins et al. 2000) and magic angle spinning 1H
NMR spectroscopy of ex vivo brain samples (Tsang et al.
2006) were used to study neurochemical changes in multiple
brain metabolites.
Recent technical and methodological developments in
high-ﬁeld in vivo NMR spectroscopy have dramatically
increased the neurochemical information content achievable
from in vivo 1H NMR spectra. Concentrations of up to 18
brain metabolites (termed a neurochemical proﬁle) can be
reliably quantiﬁed from the ultra-short echo-time 1H NMR
spectra acquired at 9.4 T (Pfeuffer et al. 1999; Tkac et al.
2003, 2004). This approach was used to reveal alterations in
the neurochemical proﬁle of quinolinic acid-lesioned rat
striatum (Tkac et al. 2001). However, this acute excitotoxic
model of HD cannot address speciﬁc mechanisms of poly-
glutamine pathophysiology. Therefore, we decided to study a
well established genetic model of HD using high performance
in vivo 1H NMR spectroscopy at 9.4 T. The aim of the present
study was to characterize the neurochemical proﬁle of the
striatum of R6/2 mice (Mangiarini et al. 1996) and monitor its
changes at two time points during disease progression.
Methods
R6/2 Mice
Animal breeding and experiments were performed according to
procedures approved by the University of Minnesota Institutional
Animal Care andUseCommittee. R6/2 founderswere purchased from
the JacksonLaboratories (BarHarbor,ME,USA) and bred by crossing
transgenic males and wild type (WT) females at 5 weeks of age.
Offspring were genotyped according to established procedures
(Mangiarini et al. 1996)and the Jackson Laboratory). In brief, DNA
was puriﬁed from blood derived from the tail vein of recently weaned
mice using standard practices (Gentra). PCR of tail DNA was
performed according to protocols provided by the Jackson Laboratory
using oligonucleotide primersOIMR494 (CGGCTGAGGCAGCAG-
CGGCTGT) and OIMR495 (GCAGCAGCAGCAGCAACAGCC-
GCCACCGCC) (University ofMinnesotaMicrochemical Facility) in
AM buffer, 10% DMSO, 200 mmol/L dNTP’s, 10 ng/mL primers
with 0.5 U/mL Taq polymerase (Boehringer Mannheim, Gaithers-
burg, MD, USA). Cycling conditions were 90¢¢@ 94C, 35 cycles @
(30¢¢ @ 94C, 30¢¢ @ 65C, 90¢¢ @ 72C), 10¢ @ 72C. Reaction
products were analyzed on a 3% agarose gel (Bio-Rad, Hercules, CA,
USA) run at 150 V for 45 min. Transgene detection was facilitated
using 100 bp oligonucleotide ladder (Bio-Rad) and illumination by
GelStar (Cambrex Bio Science, Baltimore, MD, USA).
Animal preparation
Anesthesia was induced and maintained by ﬂowing a gas mixture
(O2 : N2O = 1 : 1) containing 1.5–2.0% of isoﬂurane through the
chamber. For R6/2 mice, isoﬂurane levels were reduced to 1.25%
during the experiment. Spontaneously breathing mice were ﬁxed in
a cylindrical chamber and the air temperature surrounding the
chamber was maintained at 30C by warm water circulation. The
typical duration of the study for a single animal was approximately
1 h, but never exceeded 90 min. In vivo 1H NMR spectra were
collected from 8 (n = 7) and 12 (n = 6) week-old R6/2 mice and
from 8 (n = 8) and 12 (n = 9) week-old WT littermate controls.
In vivo 1H NMR spectroscopy
All experiments were performed on a 9.4 T/31 cm magnet (Magnex
Scientiﬁc, Abingdon, UK) equipped with an 11 cm gradient coil
insert (300 mT/m, 500 ls) and strong custom-designed second-
order shim coils (Magnex Scientiﬁc, Abingdon, UK) (Tkac et al.
2004). The magnet was interfaced to a Varian INOVA console
(Varian, Inc., Palo Alto, CA, USA). A quadrature surface RF coil
with two geometrically decoupled single-turn coils (of 14 mm
diameter) was used for both RF transmission and reception. All ﬁrst-
and second-order shim terms were automatically adjusted using
FASTMAP with EPI readout (Gruetter 1993; Gruetter and Tkac
2000). Ultra-short echo-time STEAM (echo time TE = 2 ms,
middle period TM = 20 ms, repetition time TR = 5 s, number of
transients NT = 160) combined with outer volume suppression and
VAPOR water suppression was used for localization (Tkac et al.
1999, 2004). Data were saved as arrays of FIDs (four transients per
FID), corrected for the frequency drift, summed, and ﬁnally
corrected for residual eddy current effects using the reference water
signal. The position of the volume of interest (VOI) was selected
based on multi-slice RARE images. VOIs were centered in the left
striatum at the level of the anterior commissure. The size of the VOI
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(7–12 lL) was adjusted to ﬁt the anatomical structure of striatum,
exclude the lateral ventricle, and to minimize partial volume effects.
Quantification and statistics
In vivo 1H NMR spectra were analyzed using LCModel (Provencher
1993). The unsuppressed water signal measured from the same VOI
was used as an internal reference for the quantiﬁcation, assuming
80% brain water content. The LCModel analysis calculates the best
ﬁt to the experimental spectrum as a linear combination of model,
solution spectra of brain metabolites. The following 19 metabolites
were included in the basis set: alanine (Ala), ascorbate (Asc),
aspartate, creatine (Cr), c-aminobutyric acid (GABA), glucose
(Glc), glutamate (Glu), glutamine (Gln), glutathione (GSH),
glycerophosphorylcholine (GPC), myo-inositol (myo-Ins), lactate
(Lac), N-acetylaspartate (NAA), N-acetylaspartylglutamate
(NAAG), phosphocreatine (PCr), phosphorylcholine (PCho), phos-
phorylethanolamine (PE), scyllo-inositol, and taurine (Tau). In
addition, the spectrum of fast relaxing macromolecules, experi-
mentally measured in the mouse brain with an inversion recovery
experiment using a short repetition time (TR = 2.0 s, inversion
time = 0.675 s), was included in the basis set as previously
described (Pfeuffer et al. 1999; Tkac et al. 2004). Most of
metabolites were quantiﬁed with Cramer-Rao lower bounds (CRLB)
of 3–35%, corresponding to estimated errors in metabolite concen-
trations of 0.3–0.5 lmol/g. Aspartate and scyllo-inositol were
quantiﬁed with CRLB > 35% in more than 50% of cases and
therefore were eliminated from further analysis. Also Ala data from
12-week-old R6/2 mice were not used for further evaluation because
of high CRLB. Because of the consistent quantiﬁcation of GPC and
PCho with CRLB below 35% from all individual animals, their
concentrations were reported separately despite negative correla-
tions between them in the LCModel ﬁtting algorithm (r = )0.82).
Two different statistical procedures were applied to identify
changes in metabolite levels. Only comparisons identiﬁed as
signiﬁcantly different in both tests were reported. Initially, two-
tailed t-tests were used to compare metabolite concentrations from
striata of WT and R6/2 mice of the same age and to compare
metabolite concentrations of the same strains measured at 8 and
12 weeks. To correct for multiple comparisons, p-value thresholds
p < 0.01 (*), p < 0.002 (**), and p < 0.0002 (***) were used to
determine the statistical signiﬁcance. In addition, p-values for
metabolite changes were ranked and evaluated using a false
discovery rate procedure (Benjamini and Hochberg 1995). The
false discovery rate was set so that only one of ﬁfty identiﬁed
metabolite changes might be erroneous (q = 0.02). Analysis of the
effects of age and genotype on the summed concentrations
(Gln + Glu, Cr + PCr, GPC + PCho) and concentration ratios
(Glu/Gln, PCr/Cr, GPC/PCho) was performed by two-way analysis
of variance followed by post hoc tests with Bonferroni correction
(two-way ANOVA, Graphpad Prism, 4.01). For these additional post-
test comparisons, p < 0.05 (*), p < 0.001 (**), p < 0.001 (***)
were considered signiﬁcant.
Results
In vivo 1H NMR spectra were acquired from striata of R6/2
and WT mice at 8 and 12 weeks of age (Fig. 1).
Corresponding MR images were used to position VOIs in
left striatum (Fig. 1 insets). The VOI size was adjusted
according to brain morphology, taking into account progres-
sive striatal and cortical atrophy and enlarged ventricles of
the R6/2 mice. Shimming resulted in water linewidths of 12–
14 Hz with concomitant creatine linewidths of 10–12 Hz.
Resulting high spectral resolution enabled unambiguous
signal assignment. In addition to the commonly resolved
signals of NAA, Cr + PCr, and choline-containing com-
pounds (GPC + PCho), resonances of several other brain
metabolites, such as Gln, Glu, myo-Ins, and Tau were clearly
resolved. Changes between the neurochemical proﬁles of R6/
2 and WT mice were evident from visual inspection of
corresponding 1H NMR spectra (Fig. 1). At 8 weeks of age,
reductions in NAA and increases in GPC + PCho, Gln, and
Cr + PCr were apparent in spectra from R6/2 mice compared
with WT controls. At 12 weeks of age, these changes were
more pronounced and a considerable increase in the Tau
signal was observed.
Neurochemical proﬁles composed of seventeen brain
metabolites were reliably quantiﬁed using LCModel ﬁtting
analysis from each spectrum. To examine metabolite changes
associated with HD, neurochemical proﬁles of R6/2 mice and
WT controls measured at 8 and 12 weeks were compared
(Fig. 2). At 8 weeks of age, the most striking changes
associated with HD were increases in concentrations of Cr
(+38%), Gln (+41%), and GPC (+60%) (Fig. 2, Table 1).
Also notable was an increase in GSH (+36%) and a decrease
in NAA levels ()16%). At 12 weeks of age, concentrations
Gln and GPC continued to increase (+113% and +206%,
respectively), Cr and GSH remained elevated and NAA
decreased slightly ()22%). Additional concentration changes
were observed in six more metabolites: increases in Asc, PCr,
Glu, myo-Ins, Tau and a decrease in PE (Fig. 2, Table 1). An
increase in Tau (36%) was the most noticeable change at
12 weeks (Figs 1 and 2). Ala, readily detected in WT
controls, was below the detection threshold in the 12 week
old R6/2 mice, suggesting a decrease in Ala concentration.
Signiﬁcant age-related changes in the neurochemical
proﬁle of WT mice were not found (Fig. 2, Table 1). A
decrease in Glu concentration should be viewed only as a
trend, because it did not pass both the statistical tests (Table
1). In the R6/2 mice, progressive increases in concentration
of PCr, Gln, Glu, Tau and GPC were observed at 12 weeks
relative to 8-week-old mice. Signiﬁcant decreases in con-
centrations of Glc and Lac between 8 and 12 weeks were
observed in R6/2 mice (Fig. 2, Table 1).
To facilitate comparison of these data with previously
published spectral analyses reporting relative signal intensi-
ties of total Cr, choline-containing compounds and combined
glutamate and glutamine (Glx), the sums Cr + PCr,
GPC + PCho and Gln + Glu and the concentration ratios,
PCr/Cr, GPC/PCho and Glu/Gln, were calculated (Fig. 3).
Concentration of Cr + PCr was highly elevated in striatum of
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R6/2 mice at both ages compared with WT controls (Fig. 3a).
However, the PCr/Cr ratio (Fig. 3b) changed between 8 and
12 weeks of age in the R6/2 mice, although neither of these
differed signiﬁcantly with respect to WT controls. Concen-
tration of Gln + Glu did not change between R6/2 and WT
mice at 8 weeks, but rose signiﬁcantly at 12 weeks in R6/2
mice (Fig. 3a). At 8 and 12 weeks of age, the Glu/Gln ratio
was signiﬁcantly decreased (by )36% and )0.46%, respect-
Fig. 2 Metabolite concentrations quanti-
fied from striata of wild type and R6/2 mice
at 8 and 12 weeks of age. Statistically sig-
nificant differences are noted for compari-
sons between metabolite concentrations of
R6/2 and wild type mice at each age. For
comparisons between ages within each
strain, see Table 1. Data represent
mean ± SD, n = 6–9. Significance level:
*p < 0.01, **p < 0.002, ***p < 0.0002.
Fig. 1 Representative in vivo 1H NMR spectra measured from striata
of Huntington’s disease transgenic R6/2 and wild type mice at 8 and
12 weeks of age. Insets: MR images with the selected volume of
interest centered rostrocaudally at the level of the anterior commis-
sure. Arrows indicate changes of a specific metabolite in R6/2 mice
relative to age matched WT control. STEAM, TE = 2 ms, TR = 5 s,
NT = 160. Processing: Gaussian multiplication (r = 0.085 s), FT and
zero-order phase correction. No water signal removal or baseline
correction was applied.
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ively) in transgenics relative to controls (Fig. 3b). Both sum
GPC + PCho and GPC/PCho ratio increased in striatum of
R6/2 mice when compared with WT controls, reﬂecting the
progressive increases in GPC (Fig. 2).
To visualize metabolite concentrations quantiﬁed from
individual mice and to investigate the relationship between
them, pairs of metabolites that changed the most were
selected for scatter plots (Fig. 4). While all six scatter plots
discriminate HD mice from WT controls at both ages,
separation between those two groups was most evident for
pairs of Gln versus Cr + PCr (Fig. 4c) and NAA versus
Cr + PCr (Fig. 4f). In addition, clusters of data from 12 and
8 week-old R6/2 mice were distinguishable in all scatter
plots (Figs. 4a–e) except the NAA versus Cr + PCr plot (Fig.
4f). In the R6/2, concentrations of GPC, Gln, PCr and Tau
appear to increase progressively with age. Gln concentrations
correlated with GPC (Fig. 4a, r = 0.81, p = 0.0008), PCr
(Fig. 4e, r = 0.84, p = 0.0003) and Tau (not shown,
r = 0.82, p = 0.0006). Variations in metabolite levels of
Gln, GPC, PCr, and Tau were greater in the older, more
severely effected R6/2 mice, suggesting differences in
disease progression among individual animals. Indeed, the
data points with the highest values of GPC, Tau, PCr, and
second highest Gln value came from the same animal (Fig. 4,
upside-down triangle).
Discussion
These data represent the ﬁrst non-invasive, longitudinal
measurements of absolute metabolite concentrations from a
speciﬁc brain region in a transgenic mouse model of
Huntington’s disease. Striatal neurochemical proﬁles of 17
metabolites, were repeatedly measured from the same
animals as disease progressed. This set of metabolites was
similar to the previously reported in vitro studies of R6/2
mice using tissue extracts (Jenkins et al. 2000) or tissue
samples (Tsang et al. 2006). In addition, in vivo measure-
ments eliminated undesirable catabolic processes that occur
during ex vivo sample handling and enabled detection of
labile compounds, e.g., PCr. Precise metabolite quantiﬁcation
and high reproducibility resulted in identiﬁcation of disease
progression among individual animals and clearly distin-
guished HD transgenics from non-diseased littermates. Key
methodological factors enabling precise metabolite quantiﬁ-
cation included: (i) increased sensitivity and chemical shift
dispersion at 9.4 T; (ii) efﬁcient automatic adjustment of
Table 1 Relative changes in striatal metabolite concentrations
between WT and R6/2 mice at 8 and 12 weeks of age and between
different ages of the same strain
Metabolite
% Change in R6/2
relative to WT
% Change at
12 weeks relative
to 8 weeks
At 8
weeks
At 12
weeks WT R6/2
Mac 1 )2 )3 )6
Ala )25 )15
Asc 16 62* )21 10
Cr 38*** 23** 3 )8
PCr 12 43*** 0 28*
GPC 60*** 206*** )13 66**
PCho 19 )3 33 8
GABA )7 10 )15 0
Glc 33 )23 )2 )44*
Gln 41*** 113*** )15 28**
Glu )9 16** )8 17**
GSH 36* 39** 8 10
myo-Ins 11 25*** )8 3
Lac 14 )23 )6 )36*
NAA )16** )22*** 0 )8
NAAG 16 13 )6 )8
PE )15 )22* )3 )11
Tau )2 36*** 1 39**
Statistical comparisons were made using absolute metabolite con-
centrations (Fig. 2) and are repeated here for convenience. Signifi-
cance level: *p < 0.01, **p < 0.002, ***p < 0.0002.
(a) (b)
Fig. 3 Summed concentrations (a) and concentration ratios (b) of
selected pairs of metabolites (Gln and Glu, PCr and Cr, GPC and
PCho) that are difficult to resolve at lower magnetic field strengths
(mean ± SD). Metabolites quantified from striata of R6/2 and wild type
mice at 8 and 12 weeks of age. Statistically significant differences are
shown for comparisons between R6/2 and wild type mice at each age.
Significance level: *p < 0.05, **p < 0.01, ***p < 0.001. Additionally,
significant differences between 8 and 12-week-old R6/2 mice were
found for Gln + Glu (p < 0.001), GPC + PCho (p < 0.001), PCr/Cr
(p < 0.01) and GPC/PCho (p < 0.001).
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magnetic ﬁeld homogeneity (shimming); (iii) a pulse
sequence providing high localization performance; (iv)
minimization of T2 relaxation and J-evolution with ultra-
short TE; and (v) LCmodel analysis that included the
macromolecule spectrum in the basis set and the water signal
as an internal reference. The resulting high-resolution spectra
reliably quantiﬁed individual metabolites with similar spec-
tral patterns, such as Gln and Glu, PCr and Cr or GPC and
PCho.
By comparing striatal neurochemical proﬁles of HD
transgenic and WT mice a pattern of disease-related changes
in metabolic homeostasis at different ages became evident.
At 8 weeks of age, metabolic changes reﬂected the mid-
course disease phenotype. Increased concentrations of Gln,
GPC, and Cr + PCr and decreased NAA and the Glu/Gln
ratio clearly discriminated individual HD transgenic R6/2
mice from WT littermate controls. Surprisingly, the charac-
teristic changes in Cr, Cr + PCr, GSH, NAA and Glu/Gln
observed at 8 weeks were not further progressive with
increasing age. By 12 weeks, as these animals approached
the end of life (Mangiarini et al. 1996), additional metabolic
changes characterized this later disease state. Concentrations
of metabolites such as Tau, Lac and Glu only changed late in
the animal’s lifespan, potentially identifying a more
advanced disease state. Concentrations of Gln, GPC and
PCr, as well as the ratio GPC/PCho increased progressively
with the age of R6/2 mice. Positive correlations between
concentrations of Gln and PCr, GPC or Tau suggested a link
between observed changes of these metabolites and the
progress of the disease in individual HD transgenic mice.
Changes observed at 12 weeks in metabolites, such as PCr,
Asc, PE and myo-Ins, might have begun earlier, but failed to
reach signiﬁcance by our strict statistical criteria. Thus, we
have identiﬁed metabolic markers that may characterize
different stages of disease in this mouse model of HD.
Among individual R6/2 mice, concentrations of Gln
correlated with those of GPC, PCr and Tau, suggesting
parallel changes of the underlying mechanisms. As the R6/2
mice became older, the metabolite concentration ranges
became broader and farther away from normative values. The
scatter of points among mice of similar ages may indicate
that disease progression was not identical among animals.
While we have no independent measures of disease stage in
these animals, we suggest that the concentration changes of
(a) (b)
(c) (d)
(e) (f)
Fig. 4 Scatter plots of selected metabolite
concentrations quantified from individual
mice distinguished between R6/2 and wild
type at 8 and 12 weeks of age. For the R6/2
data, dotted lines represent correlation
between Gln and GPC (a; r = 0.81,
p = 0.0008), Gln and PCr (e; r = 0.84,
p = 0.0003), Gln and Tau (not shown,
r = 0.82, p = 0.0006). To illustrate the abil-
ity to track individual animals, values from
one particular R6/2 mouse are highlighted
with an inverted, filled triangle.
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these metabolites may be useful in monitoring disease
progression. A multiparameter approach to follow metabolite
changes may prove useful in monitoring disease progression,
especially with respect to therapeutic trials. Indeed, charac-
teristic changes in absolute brain metabolite concentrations
have been reported for humans with adrenoleukodystrophy
examined at 4 T (Oz et al. 2005).
A signiﬁcant increase in Cr + PCr, typically reported as
tCr, was observed at both ages. As tCr is typically used in
reporting ratios of other metabolites, care must be taken in
interpreting this type of data (Jenkins et al. 1993; Taylor-
Robinson et al. 1996; Jenkins et al. 1998; Hoang et al. 1998;
Jenkins et al. 2000, 2005). The increased Cr + PCr at
8 week was the result of Cr alone, and not PCr. Considering
the homeostatic need to maintain normal PCr levels and the
reported decrease of creatine kinase mRNA in R6/2 striatum
(Luthi-Carter et al. 2002), an up-regulation of Cr may occur.
An increase in kinetic parameters for the creatine kinase
reaction has been reported in the 3NP model of HD
(Kasparova et al. 2005). Decreased respiration and ATP
production would also contribute to an increased demand for
total creatine (Seong et al. 2005; Milakovic and Johnson
2005; Puranam et al. 2006). A similar compensatory homeo-
static response was observed in the increase in the antioxi-
dants, Asc and GSH probably in response to the reported
oxidative stress in R6/2 (Tabrizi et al. 2000).
At 12 weeks, the pattern of metabolite changes was not
simply an exaggeration of those seen at 8 weeks, as might be
expected for a single mechanism mediating an increasingly
progressive disease. Between 8 and 12 week, PCr levels and
PCr/Cr ratio in the R6/2 striatum increased while Cr + PCr
remained elevated. As disease phenotype continuously
worsens with age in R6/2, as typiﬁed by the continuously
increasing Gln, Tau and GPC concentrations, the increase in
PCr/Cr ratio may represent a decrease in striatal energy
demands rather than an improved energetic status or
mitochondrial function. Indeed, striatal glucose utilization
decreases between 8 and 12 weeks in R6/2 animals (Wang
et al. 2005). Progressive tissue atrophy, as suggested by the
elevated GPC, a marker of membrane breakdown and altered
dendritic morphology, neuronal excitability and neurotrans-
mission (Nitsch et al. 1992; Klapstein et al. 2001), may
mediate the decreased energy demand. Similarly, PCr
increased relative to Cr in chronically hypoxic rats or insulin
hypoglycemia, conditions expected to decrease energy
consumption (Thurston et al. 1977; Raman et al. 2005).
Different disease-related processes may be responsible for
the changes in Glu and Gln observed at the two time points
as well. At 8 weeks, the increased Gln may represent an
imbalance in the Glu–Gln cycling through neurons and
astrocytes reﬂecting compromised glutamatergic neurotrans-
mission. Indeed, highly signiﬁcant decreases in Glu/Gln ratio
was observed at 8 weeks despite the unchanged sum of Gln
and Glu. The increase in Gln steady-state concentration
occurred despite the abnormal astrocytic glutamate uptake
following down-regulation of glutamate transporters (Li-
evens et al. 2001; Behrens et al. 2002). The source of the
increased Gln was not readily apparent, as both glutamine
synthase and phosphate activated glutaminase activities are
decreased in R6/2 (Butterworth et al. 1985; Lievens et al.
2001). Net Gln synthesis could not account for the continu-
ous Gln increase, as the sum, Glu + Gln, was not increased
at this time. While the excess polyglutamines incorporated in
the Huntingtin protein or protein fragments would not be
expected to contribute to the 1H NMR signal, an increase in
soluble glutamine monomers as a consequence of Hunting-
ton degradation remains a remote possibility. At 12 weeks,
Gln + Glu increased signiﬁcantly. Astrocyte proliferation
accompanies HD and could account for the increased Gln
and myo-Ins, which are predominantly found in astrocytes
(Norenberg and Martinez-Hernandez 1979; Brand et al.
1993). However, this is only locally active in R6/2 mice
(Davies et al. 1999; Turmaine et al. 2000). The increased
Glu could also reﬂect its accumulation as an osmolyte at this
stage in the disease process. Indeed, other osmolytes, such as
Tau and myo-Ins, are also prominently elevated at 12 weeks.
Tau is elevated in the putamen of HD patients (Grams-
bergen et al. 1986) and in the cortex and striatum of aged R6/
2 mice (Jenkins et al. 2000, 2005). We also found a 36%
elevation in taurine in 12, but not 8-week-old R6/2 mice. Tau
has been assigned numerous functions in the CNS, including
neuromodulator, neurotransmitter, osmolyte and neuropro-
tectant (Foos and Wu 2002). Appreciable amounts of Tau are
released from astrocytes in response to hyposmolarity,
hypoxia, ischemia, oxidative stress, and metabolic toxins
(Reymond et al. 1996; Saransaari and Oja 2000; Foos and
Wu 2002). Strikingly, the increased Tau, Gln, Glu, PCr, total
Cr, GPC and myo-Ins and decreased Lac observed in R6/2
mice at 12 weeks resemble the pattern of changes in these
metabolites observed by both analytical methods and ex vivo
1H NMR spectroscopy following hypernatremia (Thurston
et al. 1983; Heilig et al. 1989). Hypernatremia could result
from insufﬁcient energy to power the Na–K–ATPase to
maintain intracellular ion concentrations or the reported
decrease in Na–K–ATPase mRNA in R6/2 mice (Luthi-
Carter et al. 2002).
The decrease in NAA concentration and subsequent
increase in Tau concentration verify that conclusions reached
in earlier HD studies, reporting signal ratios relative to tCr
signal, indeed reﬂected decreases in NAA and increases in
Tau (Jenkins et al. 2000, 2005). However, the reported 50–
60% decrease of NAA/tCr (Jenkins et al. 2000, 2005) is
attributable to a 16–22% drop in NAA combined with a 27–
31% increase in Cr + PCr demonstrated here. The decreased
levels of NAA in R6/2 mice may reﬂect mitochondrial
impairment (Bates et al. 1996), decreased neuronal integrity
or neuronal dysfunction as consistently observed in neuro-
logical diseases (Demougeot et al. 2004).
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The largest percent change in a metabolite was the
increase in GPC at 12 weeks. Increases in GPC levels in
cortical gray matter measured analytically from severely
demented Alzheimers disease brains have been attributed to
membrane breakdown (Nitsch et al. 1992). However, this
same study did not ﬁnd increases in GPC in human
Huntington’s disease cortical gray matter. Alternatively,
elevated GPC levels could result from inactivation of its
catabolism. GPC cholinephosphodiesterase, an enzyme that
catalyzes conversion of GPC into glycerol and PCho,
undergoes oxidative inactivation (Sok 1998). GPC choline-
phosphodiesterase activity, selectively enriched in oligo-
dendrocytes, was decreased in three different rodent models
of demyelination (Yuan et al. 1992). Oxidative damage is
characteristic of R6/2 brains (Tabrizi et al. 2000) and white
matter damage occurs in HD (Ciarmiello et al. 2006). Thus,
the possibility exists that the increase in GPC but not PCho in
R6/2 striatum may reﬂect metabolic changes in white matter
tracts that traverse this region.
The pattern of metabolite changes observed in the R6/2
mouse contrast with those observed in two other models of
HD. The transgenic R6/2 mouse overexpresses an N-terminal
fragment of human Huntingtin with 150 or more CAG
repeats and is considered to model juvenile onset HD, the
severest form of the disease. quinolinic acid-induced excito-
toxicity has been proposed as a model of the ﬁnal steps in the
cell death pathway in HD (Beal et al. 1986). Chronic
exposure to the complex II inhibitor, 3NP, has been used to
mimic the metabolic insufﬁciency proposed to accompany
HD (Brouillet et al. 1993). In normal rats and mice, basal
levels of metabolites detectable by 1H NMR spectrosocpy are
comparable, making comparisons of these disease models
plausible (Pfeuffer et al. 1999; Tkac et al. 2004). While
NAA decreases in all three models, other metabolites do not
change in similar manner. In both QA-treated rats and R6/2
mice at 8 weeks, Gln increased and Glu decreased. Other
metabolite changes, however, are not similar. By 12 weeks in
R6/2, Glu concentration increased. In R6/2, Tau, GSH and
Cr + PCr increased, while in the QA-treated rats, these
metabolites decreased (Tkac et al. 2001). Lac, GPC + PCho,
myo-Ins, and PE remained unchanged in QA-treated rats
despite changes in R6/2 (Tkac et al. 2001). Total Cr and
choline-containing compounds also decreased in the striatum
of the 3NP-treated baboon (Dautry et al. 1999). These
comparisons suggest that acute, relatively synchronous
excitotoxic cell death produces a metabolic pattern quite
distinct from that observed in the transgenic animal where
cell death, if present, will affect only a small proportion of
neurons at any one time. The distinct metabolite proﬁle of the
R6/2 mouse indicated that if this is a faithful model of HD,
the neurodegenerative mechanisms may be more complex
than either TCA and electron transport impairment or
excitotoxicty. Thus, the metabolic changes observed in R6/
2 may reﬂect the ongoing balance between multiple proces-
ses: initial compensatory changes, secondary consequences,
and in later stages, the denouement to cellular dysfunction
and death.
Acknowledgements
We thank Dr Jean H. Thurston for insightful discussions and
Dorothee Aeppli, Ph.D., Biostatistics Consulting Lab for statistical
consultations. This work was supported by NIH F30-MH12157,
NIH P41 RR08079, the Keck Foundation, the MIND Institute, the
Biomedical Engineering Institute of the University of Minnesota and
the Huntington’s Disease Society of America.
References
Aylward E. H., Sparks B. F., Field K. M. et al. (2004) Onset and rate of
striatal atrophy in preclinical Huntington disease. Neurology 63,
66–72.
Bates T. E., Strangward M., Keelan J., Davey G. P., Munro P. M. and
Clark J. B. (1996) Inhibition of N-acetylaspartate production:
implications for 1H MRS studies in vivo. Neuroreport 7, 1397–
1400.
Beal M. F. (2005) Mitochondria take center stage in aging and neuro-
degeneration. Ann. Neurol. 58, 495–505.
Beal M. F., Kowall N. W., Ellison D. W., Mazurek M. F., Swartz K. J.
and Martin J. B. (1986) Replication of the neurochemical charac-
teristics of Huntington’s disease by quinolinic acid. Nature 321,
168–171.
Behrens P. F., Franz P., Woodman B., Lindenberg K. S. and Land-
wehrmeyer G. B. (2002) Impaired glutamate transport and glu-
tamate-glutamine cycling: downstream effects of the Huntington
mutation. Brain JID - 0372537 125, 1908–1922.
Benjamini Y. and Hochberg Y. (1995) Controlling the false discovery
rate: a practical and powerful approach to multiple testing. Roy.
Stat. Soc. B 1, 289–300.
Bonavita S., Di Salle F. and Tedeschi G. (1999) Proton MRS in neu-
rological disorders. Eur. J. Radiol. 30, 125–131.
Brand A., Richter-Landsberg C. and Leibfritz D. (1993) Multinuclear
NMR studies on the energy metabolism of glial and neuronal cells.
Dev. Neurosci. 15, 289–298.
Brouillet E., Jenkins B. G., Hyman B. T., Ferrante R. J., Kowall N. W.,
Srivastava R., Roy D. S., Rosen B. R. and Beal M. F. (1993) Age-
dependent vulnerability of the striatum to the mitochondrial toxin
3-nitropropionic acid. J. Neurochem. 60, 356–359.
Butterworth J., Yates C. M. and Reynolds G. P. (1985) Distribution of
phosphate-activated glutaminase, succinic dehydrogenase, pyru-
vate dehydrogenase and gamma-glutamyl transpeptidase in post-
mortem brain from Huntington’s disease and agonal cases.
J. Neurol. Sci. 67, 161–171.
Ciarmiello A., Cannella M., Lastoria S., Simonelli M., Frati L.,
Rubinsztein D. C. and Squitieri F. (2006) Brain white-matter
volume loss and glucose hypometabolism precede the clin-
ical symptoms of Huntington’s disease. J. Nucl. Med. 47, 215–
222.
Dautry C., Conde F., Brouillet E., Mittoux V., Beal M. F., Bloch G. and
Hantraye P. (1999) Serial 1H NMR spectroscopy study of meta-
bolic impairment in primates chronically treated with the succinate
dehydrogenase inhibitor 3-nitropropionic acid. Neurobiol. Dis. 6,
259–268.
Davies S. W., Turmaine M., Cozens B. A., Raza A. S., Mahal A.,
Mangiarini L. and Bates G. P. (1999) From neuronal inclusions to
neurodegeneration: neuropathological investigation of a transgenic
8 I. Tkac et al.
Journal Compilation  2007 International Society for Neurochemistry, J. Neurochem. (2007) 10.1111/j.1471-4159.2006.04323.x
 2007 The Authors
mouse model of Huntington’s disease. Philos. Trans. R. Soc. Lond.
B Biol. Sci. 354, 981–989.
van Dellen A., Welch J., Dixon R. M., Cordery P., York D., Styles P.,
Blakemore C. and Hannan A. J. (2000) N-Acetylaspartate and
DARPP-32 levels decrease in the corpus striatum of Huntington’s
disease mice. Neuroreport 11, 3751–3757.
Demougeot C., Marie C., Giroud M. and Beley A. (2004) N-acetyl-
aspartate: a literature review of animal research on brain ischaemia.
J. Neurochem. 90, 776–783.
Dunlop D. S., Mc Hale D. M. and Lajtha A. (1992) Decreased brain
N-acetylaspartate in Huntington’s disease. Brain Res. 580, 44–48.
Duyao M., Ambrose C., Myers R., Novelletto A., Persichetti F., Frontali
M., Folstein S., Ross C., Franz M. and Abbott M. (1993) Trinu-
cleotide repeat length instability and age of onset in Huntington’s
disease. Nat. Genet. 4, 387–392.
Foos T. M. and Wu J. Y. (2002) The role of taurine in the central nervous
system and the modulation of intracellular calcium homeostasis.
Neurochem. Res. 27, 21–26.
Garseth M., Sonnewald U., White L. R., Rod M., Zwart J. A., Nygaard
O. and Aasly J. (2000) Proton magnetic resonance spectroscopy of
cerebrospinal ﬂuid in neurodegenerative disease: indication of glial
energy impairment in Huntington chorea, but not Parkinson dis-
ease. J. Neurosci. Res. 60, 779–782.
Gramsbergen J. B., Veenma-Van der Duin L., Venema K. and Korf J.
(1986) Cerebral cation shifts and amino acids in Huntington’s
disease. Arch. Neurol. 43, 1276–1281.
Gruetter R. (1993) Automatic, localized in vivo adjustment of all ﬁrst-
and second-order shim coils. Magn. Reson. Med. 29, 804–811.
Gruetter R. and Tkac I. (2000) Field mapping without reference scan
using asymmetric echo-planar techniques. Magn. Reson. Med. 43,
319–323.
Harms L., Meierkord H., Timm G., Pfeiffer L. and Ludolph A. C. (1997)
Decreased N-acetyl-aspartate/choline ratio and increased lactate in
the frontal lobe of patients with Huntington’s disease: a proton
magnetic resonance spectroscopy study. J. Neurol. Neurosurg.
Psychiatry 62, 27–30.
Heilig C. W., Stromski M. E., Blumenfeld J. D., Lee J. P. and Gullans
S. R. (1989) Characterization of the major brain osmolytes that
accumulate in salt-loaded rats. Am. J. Physiol. 257, F1108–F1116.
Hoang T. Q., Bluml S., Dubowitz D. J., Moats R., Kopyov O., Jacques
D. and Ross B. D. (1998) Quantitative proton-decoupled 31P MRS
and 1H MRS in the evaluation of Huntington’s and Parkinson’s
diseases. Neurology 50, 1033–1040.
Huntington G. (1872) On chorea. Adv. Neurol. 1, 33–35.
Huntington’s Disease Collaborative Research Group. (1993) A novel
gene containing a trinucleotide repeat that is expanded and unstable
on Huntington’s disease chromosomes. Cell 72, 971–983.
Jenkins B. G., Koroshetz W. J., Beal M. F. and Rosen B. R. (1993)
Evidence for impairment of energy metabolism in vivo in Hunt-
ington’s disease using localized 1H NMR spectroscopy. Neurology
43, 2689–2695.
Jenkins B. G., Rosas H. D., Chen Y. C., Makabe T., Myers R., Mac-
Donald M., Rosen B. R., Beal M. F. and Koroshetz W. J. (1998) 1H
NMR spectroscopy studies of Huntington’s disease: correlations
with CAG repeat numbers. Neurology 50, 1357–1365.
Jenkins B. G., Klivenyi P., Kustermann E., Andreassen O. A., Ferrante
R. J., Rosen B. R. and Beal M. F. (2000) Nonlinear decrease over
time in N-acetyl aspartate levels in the absence of neuronal loss and
increases in glutamine and glucose in transgenic Huntington’s
disease mice. J. Neurochem. 74, 2108–2119.
Jenkins B. G., Andreassen O. A., Dedeoglu A., Leavitt B., Hayden M.,
Borchelt D., Ross C. A., Ferrante R. J. and Beal M. F. (2005)
Effects of CAG repeat length, HTT protein length and protein
context on cerebral metabolism measured using magnetic reson-
ance spectroscopy in transgenic mouse models of Huntington’s
disease. J Neurochem 95, 553–562.
Kasparova S., Sumbalova Z., Horecky J., Bystricky P., Mlynarik V.,
Gvozdjakova A. and Liptaj T. (2005) New magnetic resonance
spectroscopy biomarker for monitoring neurodegenerative dis-
eases: animal models. Biomed. Pap. Med. Fac. Univ. Palacky
Olomouc. Czech. Repub. 149, 373–376.
Klapstein G. J., Fisher R. S., Zanjani H., Cepeda C., Jokel E. S.,
Chesselet M. F. and Levine M. S. (2001) Electrophysiological
and morphological changes in striatal spiny neurons in R6/2
Huntington’s disease transgenic mice. J Neurophysiol 86, 2667–
2677.
Koroshetz W. J., Jenkins B. G., Rosen B. R. and Beal M. F. (1997)
Energy metabolism defects in Huntington’s disease and effects of
coenzyme Q10. Ann Neurol 41, 160–165.
Landles C. and Bates G. P. (2004) Huntingtin and the molecular path-
ogenesis of Huntington’s disease. Fourth in molecular medicine
review series. EMBO Rep 5, 958–963.
Levine M. S., Cepeda C., Hickey M. A., Fleming S. M. and Chesselet
M. F. (2004) Genetic mouse models of Huntington’s and Parkin-
son’s diseases: illuminating but imperfect. Trends Neurosci. 27,
691–697.
Li S. H. and Li X. J. (2004) Huntingtin and its role in neuronal
degeneration. Neuroscientist 10, 467–475.
Lievens J. C., Woodman B., Mahal A., Spasic-Boscovic O., Samuel D.,
Kerkerian-Le G. L. and Bates G. P. (2001) Impaired glutamate
uptake in the R6 Huntington’s disease transgenic mice. Neurobiol
Dis. 8, 807–821.
Lodi R., Schapira A. H., Manners D., Styles P., Wood N. W., Taylor D. J.
and Warner T. T. (2000) Abnormal in vivo skeletal muscle energy
metabolism in Huntington’s disease and dentatorubropallidoluy-
sian atrophy. Ann. Neurol. 48, 72–76.
Luthi-Carter R., Hanson S. A., Strand A. D. et al. (2002) Dysregulation
of gene expression in the R6/2 model of polyglutamine disease:
parallel changes in muscle and brain. Hum. Mol. Genet. JID –
9208958 11, 1911–1926.
Mangiarini L., Sathasivam K., Seller M., Cozens B., Harper A.,
Hetherington Lawton M., Trottier Y., Lehrach H., Davies S. W. and
Bates G. P. (1996) Exon 1 of the HD gene with an expanded CAG
repeat is sufﬁcient to cause a progressive neurological phenotype in
transgenic mice. Cell 87, 493–506.
Milakovic T. and Johnson G. V. (2005) Mitochondrial respiration and
ATP production are signiﬁcantly impaired in striatal cells expres-
sing mutant Huntingtin. J. Biol. Chem. 280, 30 773–30 782.
Nance M. A. (1998) Huntington disease: clinical, genetic, and social
aspects. J. Geriatr. Psychiatry Neurol. 11, 61–70.
Nicoli F., Vion-Dury J., Maloteaux J. M., Delwaide C., Confort-Gouny
S., Sciaky M. and Cozzone P. J. (1993) CSF and serum metabolic
proﬁle of patients with Huntington’s chorea: a study by high
resolution proton NMR spectroscopy and HPLC. Neurosci. Lett.
154, 47–51.
Nitsch R. M., Blusztajn J. K., Pittas A. G., Slack B. E., Growdon J. H.
and Wurtman R. J. (1992) Evidence for a membrane defect in
Alzheimer disease brain. Proc. Natl Acad. Sci. USA 89, 1671–
1675.
Norenberg M. D. and Martinez-Hernandez A. (1979) Fine structural
localization of glutamine synthetase in astrocytes of rat brain.
Brain Res. 161, 303–310.
Oz G., Tkac I., Charnas L. R., Choi I. Y., Bjoraker K. J., Shapiro E. G.
and Gruetter R. (2005) Assessment of adrenoleukodystrophy
lesions by high ﬁeld MRS in non-sedated pediatric patients.
Neurology 64, 434–441.
Pfeuffer J., Tkac I., Provencher S. W. and Gruetter R. (1999) Toward an
in vivo neurochemical proﬁle: quantiﬁcation of 18 metabolites in
1H NMR spectroscopy of R6/2 mice 9
 2007 The Authors
Journal Compilation  2007 International Society for Neurochemistry, J. Neurochem. (2007) 10.1111/j.1471-4159.2006.04323.x
short-echo-time (1)H NMR spectra of the rat brain. J. Magn.
Reson. 141, 104–120.
Provencher S. W. (1993) Estimation of metabolite concentrations from
localized in vivo proton NMR spectra. Magn. Reson. Med. 30,
672–679.
Puranam K. L., Wu G., Strittmatter W. J. and Burke J. R. (2006)
Polyglutamine expansion inhibits respiration by increasing reactive
oxygen species in isolated mitochondria. Biochem. Biophys. Res.
Commun. 341, 607–613.
Raman L., Tkac I., Ennis K., Georgieff M. K., Gruetter R. and Rao R.
(2005) In vivo effect of chronic hypoxia on the neurochemical
proﬁle of the developing rat hippocampus. Brain Res. Dev. Brain
Res. 156, 202–209.
Reymond I., Almarghini K. and Tappaz M. (1996) Immunocytochemical
localization of cysteine sulﬁnate decarboxylase in astrocytes in the
cerebellum and hippocampus: a quantitative double immunoﬂuo-
rescence study with glial ﬁbrillary acidic protein and S-100 protein.
Neuroscience 75, 619–633.
Rosenblatt A., Abbott M. H., Gourley L. M., Troncoso J. C., Margolis
R. L., Brandt J. and Ross C. A. (2003) Predictors of neuropatho-
logical severity in 100 patients with Huntington’s disease. Ann.
Neurol. 54, 488–493.
Sanchez-Pernaute R., Garcia-Segura J. M., del Barrio A. A., Viano J. and
de Yebenes J. G. (1999) Clinical correlation of striatal 1H MRS
changes in Huntington’s disease. Neurology 53, 806–812.
Saransaari P. and Oja S. S. (2000) Taurine and neural cell damage.
Amino Acids 19, 509–526.
Sawa A., Wiegand G. W., Cooper J., Margolis R. L., Sharp A. H.,
Lawler J. F. Jr., Greenamyre J. T., Snyder S. H. and Ross C. A.
(1999) Increased apoptosis of Huntington disease lymphoblasts
associated with repeat length-dependent mitochondrial depolar-
ization. Nature Med. 5, 1194–1198.
Seong I. S., Ivanova E., Lee J. M. et al. (2005) HD CAG repeat
implicates a dominant property of huntingtin in mitochondrial
energy metabolism. Hum. Mol. Genet. 14, 2871–2880.
Sok D. E. (1998) Ascorbate-induced oxidative inactivation of Zn2+-
glycerophosphocholine cholinephosphodiesterase. J. Neurochem.
70, 1167–1174.
Tabrizi S. J., Workman J., Hart P. E., Mangiarini L., Mahal A., Bates G.,
Cooper JM and Schapira A. H. V. (2000) Mitochondrial dysfunc-
tion and free radical damage in the Huntington R6/2 transgenic
mouse. Ann. Neurol. 47, 80–86.
Taylor-Robinson S. D., Weeks R. A., Bryant D. J., Sargentoni J., Marcus
C. D., Harding A. E. and Brooks D. J. (1996) Proton magnetic
resonance spectroscopy in Huntington’s disease: evidence in favour
of the glutamate excitotoxic theory. Mov. Disord. 11, 167–173.
Thurston J. H., Hauhart R. E., Dirgo J. A. and McDougal D. B. Jr. (1977)
Insulin and brain metabolism. Absence of direct action of insulin
on K+ and Na+ transport in normal rabbit brain. Diabetes 26, 1117–
1119.
Thurston J. H., Hauhart R. E. and Schulz D. W. (1983) Effect of chronic
hypernatremic dehydration and rapid rehydration on brain carbo-
hydrate, energy, and amino acid metabolism in weanling mice.
J. Neurochem. 40, 240–245.
Tkac I., Starcuk Z., Choi I. Y. and Gruetter R. (1999) In vivo 1H NMR
spectroscopy of rat brain at 1 ms echo time. Magn. Reson. Med.
41, 649–656.
Tkac I., Keene C. D., Pfeuffer J., Low W. C. and Gruetter R. (2001)
Metabolic changes in quinolinic acid-lesioned rat striatum detected
non-invasively by in vivo (1)H NMR spectroscopy. J. Neurosci.
Res. 66, 891–898.
Tkac I., Rao R., Georgieff M. K. and Gruetter R. (2003) Developmental
and regional changes in the neurochemical proﬁle of the rat brain
determined by in vivo 1H NMR spectroscopy. Magn. Reson. Med.
50, 24–32.
Tkac I., Henry P. G., Andersen P., Keene C. D., Low W. C. and
Gruetter R. (2004) Highly resolved in vivo 1H NMR spectro-
scopy of the mouse brain at 9.4 T. Magn. Reson. Med. 52, 478–
484.
Tsang T. M., Woodman B., McLoughlin G. A., Grifﬁn J. L., Tabrizi S. J.,
Bates G. P. and Holmes E. (2006) Metabolic characterization of the
R6/2 transgenic mouse model of Huntington’s disease by high-
resolution MAS 1H NMR spectroscopy. J. Proteome. Res. 5, 483–
492.
Turmaine M., Raza A., Mahal A., Mangiarini L., Bates G. P. and Davies
S. W. (2000) Nonapoptotic neurodegeneration in a transgenic
mouse model of Huntington’s disease. Proc. Natl Acad. Sci. USA
97, 8093–8097.
Vonsattel J. P., Myers R. H., Stevens T. J., Ferrante R. J., Bird E. D.
and Richardson E. P. Jr. (1985) Neuropathological classiﬁcation
of Huntington’s disease. J. Neuropathol. Exp. Neurol. 44, 559–
577.
Wang X., Sarkar A., Cicchetti F., Yu M., Zhu A., Jokivarsi K., Saint-
Pierre M. and Brownell A. L. (2005) Cerebral PET imaging and
histological evidence of transglutaminase inhibitor cystamine
induced neuroprotection in transgenic R6/2 mouse model of
Huntington’s disease. J Neurol Sci 231, 57–66.
Yuan J., McCartney D. G., Monge M., Espinosa de Los M. A., Zalc B.,
de Vellis J. and Kanfer J. N. (1992) Glycerophosphorylcholine
phosphocholine phosphodiesterase activity in cultured oligodend-
rocytes, astrocytes, and central nervous tissue of dysmyelinating
rodent mutants. J. Neurosci. Res. 31, 68–74.
10 I. Tkac et al.
Journal Compilation  2007 International Society for Neurochemistry, J. Neurochem. (2007) 10.1111/j.1471-4159.2006.04323.x
 2007 The Authors
